Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6PE9

Crystal Structure of CD40 complexed to FAB516

6PE9 の概要
エントリーDOI10.2210/pdb6pe9/pdb
分子名称FAB Heavy chain, FAB Light chain, Tumor necrosis factor receptor superfamily member 5, ... (5 entities in total)
機能のキーワードcd40, fab, complex, immune system
由来する生物種Homo sapiens (Human)
詳細
タンパク質・核酸の鎖数15
化学式量合計336555.13
構造登録者
Argiriadi, M.A. (登録日: 2019-06-20, 公開日: 2019-08-14, 最終更新日: 2024-10-16)
主引用文献Argiriadi, M.A.,Benatuil, L.,Dubrovska, I.,Egan, D.A.,Gao, L.,Greischar, A.,Hardman, J.,Harlan, J.,Iyer, R.B.,Judge, R.A.,Lake, M.,Perron, D.C.,Sadhukhan, R.,Sielaff, B.,Sousa, S.,Wang, R.,McRae, B.L.
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
BMC Mol Cell Biol, 20:29-29, 2019
Cited by
PubMed Abstract: CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications.
PubMed: 31382872
DOI: 10.1186/s12860-019-0213-4
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.13 Å)
構造検証レポート
Validation report summary of 6pe9
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon